Poniard's picoplatin fails to impress in colorectal cancer
This article was originally published in Scrip
Executive Summary
Poniard Pharmaceuticals' only drug candidate in clinical development, the chemotherapeutic agent picoplatin, failed to impress investors with its efficacy in a Phase II trial testing it as first-line treatment in metastatic colorectal cancer (CRC), despite meeting its primary objective of showing a reduction in neurotoxicity.